DURECT is committed to transforming the treatment of acute organ injury and chronic liver diseases by advancing novel and lifesaving therapies based on its endogenous epigenetic regulator program. The company’s lead candidate, DUR-928, is the first endogenous epigenetic regulator clinically tested for difficult-to-treat diseases. DUR-928 has demonstrated the ability to regulate the expression of genes involved in lipid metabolism, inflammatory responses and cell survival.
DUR-928 has demonstrated positive efficacy and safety results as a potential treatment for patients with alcoholic hepatitis (AH), a life-threatening acute alcoholic liver disease with no approved drugs and a 28-day overall mortality rate of 26%. The drug candidate has the potential to become the first drug indicated for the treatment of AH patients. DUR-928 is also being tested as an orally administered treatment in patients with nonalcoholic steatohepatitis (NASH). In a Phase 1b trial in NASH patients, DUR-928 improved important liver enzymes, liver imaging and serum lipid profile in only 28 days.
In addition, DURECT is leveraging its proprietary drug delivery technologies to develop treatments for postoperative pain and attention-deficit hyperactivity disorder (ADHD). The company is also collaborating with Gilead Sciences to develop a new long-acting treatment for human immunodeficiency virus (HIV).